ClinicalTrials.gg
Not yet recruitingNCT07520630Updated Apr 9, 2026

Neurophysiological Markers for Prediction of Rehabilitation Outcomes After Ischemic Stroke

An interventional study of Intermittent Theta Burst Stimulation and Sham Intermittent Theta Burst Stimulation in Ischemic Stroke and Upper Limb Motor Impairment, sponsored by Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine. Not yet recruiting at 1 site in Russia. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Ischemic Stroke with a site in Russia — 13 open to participants now, 13 under way, 2 of them phase 3. Ischemic Stroke · Russia.

Started
2026
with 3 others
No phase
4 of 17
4 open now
Primary completion
2027-03
later than 5 of 12 live
Registered
13th of 17
by date
Lead sponsor
1 of 17
Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine

Among the 17 studies in Ischemic Stroke with a site in Russia, this one is one of 4 that started in 2026, is one of 4 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 13th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

13 of the 17 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ischemic Stroke with a site in Russia, or all of them as a file.
02

Study summary

The goal of this randomized controlled study is to develop and validate an integrated neurophysiological model for predicting rehabilitation potential in patients with ischemic stroke. The study focuses on identifying objective markers of brain activity associated with motor preparation and recovery.

The project includes two stages. First, healthy volunteers will participate in experimental motor and mental tasks to establish reference patterns of brain activity using electroencephalography and transcranial magnetic stimulation. These data will be used to define stable neurophysiological markers of motor network function.

In the second stage, patients in the acute and early recovery phases after ischemic stroke will be randomly assigned to receive either active intermittent theta-burst stimulation of the motor cortex or a sham procedure, in addition to standard rehabilitation. Brain activity and clinical motor function will be assessed before and after the intervention.

The study aims to determine which neurophysiological measures are sensitive to neuromodulation and are associated with clinical improvement, in order to construct a predictive model of rehabilitation outcome.

Participants will [describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items].

Read the detailed description

Stroke remains a leading cause of long-term disability worldwide. Motor recovery after ischemic stroke is highly variable, and currently available clinical scales provide limited ability to predict rehabilitation potential at the individual level. There is a need for objective, neurophysiologically grounded biomarkers that reflect motor network integrity, cortical excitability, and adaptive neuroplasticity.

The present study aims to develop and validate an integrated neurophysiological model for predicting rehabilitation outcomes in patients with ischemic stroke. The model is based on a multimodal assessment combining electroencephalography (EEG), performed during standardized ecologically valid motor and mental paradigms, and diagnostic transcranial magnetic stimulation (TMS).

The project consists of two interconnected stages.

Stage 1 (Experimental Reference Phase in Healthy Volunteers):

Healthy adult participants will perform standardized motor execution and motor imagery paradigms under EEG and surface electromyography monitoring. Cortical excitability will be assessed using diagnostic TMS. This phase is designed to identify stable neurophysiological patterns associated with motor preparation and execution, including movement-related cortical potentials, sensorimotor rhythm modulation, and measures of functional connectivity. These data will serve as reference patterns to define candidate biomarkers for subsequent clinical testing.

Stage 2 (Randomized Controlled Clinical Phase):

Patients in the acute and early recovery stages following first-ever ischemic stroke will be randomly assigned to receive either active intermittent theta-burst stimulation (iTBS) of the ipsilesional primary motor cortex or sham stimulation, in addition to standard rehabilitation therapy. The intervention course will consist of multiple stimulation sessions delivered over a two-week period.

Neurophysiological assessments (EEG and diagnostic TMS) will be conducted before and after the intervention. Clinical motor and cognitive function will be evaluated using standardized scales at baseline and post-intervention time points.

The randomized design allows evaluation of the sensitivity of candidate neurophysiological markers to neuromodulatory intervention and their association with clinical recovery dynamics. By integrating electrophysiological measures of cortical excitability, motor network synchronization, and interregional connectivity with clinical outcomes, the study seeks to identify a minimal set of objective markers capable of predicting rehabilitation response.

The ultimate objective is to construct and statistically validate a predictive model of rehabilitation potential that may support individualized planning of post-stroke neurorehabilitation strategies.

03

Conditions studied

  • Ischemic Stroke
  • Upper Limb Motor Impairment

Browse trials for

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Experimental phase:

will include healthy volunteers without contradictions to TMS

Clinical phase:

Inclusion criteria

Inclusion Criteria:

  • First-ever ischemic stroke confirmed by CT/MRI
  • 5 days - 6 months post-stroke
  • Age 40-65
  • ≥20
  • HADS \<11 for anxiety and depression
  • MRC 2-4 in upper limb
  • Modified Ashworth Scale ≤3
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Implanted electronic devices
  • Epilepsy
  • Severe cardiac arrhythmias
  • Intracranial aneurysm
  • Decompensated somatic disease
  • Pregnancy/lactation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    iTBS

    Device: Intermittent Theta Burst Stimulation

  • Sham comparator
    Sham-iTBS

    Device: Sham Intermittent Theta Burst Stimulation

Interventions

  • DeviceIntermittent Theta Burst Stimulation

    Once a day, 10 days of Intermittent Theta-Burst Stimulation (iTBS) applied to ipsilesional primary motor cortex (M1).

  • DeviceSham Intermittent Theta Burst Stimulation

    Once a day, 10 days of Sham Theta-Burst Stimulation using placebo coil

06

What researchers measure

Primary outcomes

  1. Change in Muscle Strength Assessed by the Medical Research Council Scale (MRC)

    Muscle strength of the affected upper limb assessed using the Medical Research Council (MRC) scale, ranging from 0 (no muscle contraction) to 5 (normal muscle strength). Higher scores indicate better motor function.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  2. Change in Muscle Tone Assessed by the Modified Ashworth Scale (MAS)

    Muscle tone of the affected upper limb assessed using the Modified Ashworth Scale (MAS), which ranges from 0 (no increase in muscle tone) to 4 (Affected part(s) rigid in flexion or extension). Higher scores indicate greater spasticity.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  3. Change in Upper Limb Motor Function (Fugl-Meyer Assessment - Upper Extremity)

    Upper limb motor impairment assessed using the Fugl-Meyer Assessment for the Upper Extremity (FMA-UE). Scores range from 0 to 66, with higher scores indicating better upper limb motor function.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  4. Change in Cognitive Function Assessed by Montreal Cognitive Assessment (MoCA)

    Global cognitive function assessed using the Montreal Cognitive Assessment (MoCA), a 30-point cognitive screening tool. Scores range from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

Secondary outcomes

  1. Change in Modified Rankin Scale (mRS) score

    Global disability assessed using the modified Rankin Scale (mRS). Scores range from 0 to 6, higher scores indicate greater disability.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  2. Change in Action Research Arm Test (ARAT) score

    Upper limb functional capacity assessed using the Action Research Arm Test (ARAT). Scores range from 0 to 57, with higher scores indicating better upper limb function.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  3. Change in Nine-Hole Peg Test (NHPT) completion time

    Manual dexterity assessed using the Nine-Hole Peg Test (NHPT), a timed test of fine hand dexterity. Completion time is recorded in seconds; lower times indicate better manual dexterity.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  4. Change in Frenchay Arm Test (FAT) score

    Upper limb functional performance in daily activities assessed using the Frenchay Arm Test (FAT), a 5-item test of arm and hand function after stroke. Scores range from 0 to 5, with higher scores indicating better upper limb function.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

Other outcomes

  1. Change in Event-Related Desynchronization (ERD) of Sensorimotor Rhythm

    Event-related desynchronization (ERD) of sensorimotor rhythm in the 8-30 Hz frequency range measured using scalp electroencephalography during motor execution and motor imagery tasks. ERD is expressed as percentage decrease in band power relative to a pre-movement baseline, reflecting cortical activation.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  2. Change in Event-Related Synchronization (ERS) of Sensorimotor Rhythm

    Event-related synchronization (ERS) of sensorimotor rhythm in the 8-30 Hz frequency range measured using scalp electroencephalography during motor execution and motor imagery tasks. ERS is expressed as percentage increase in band power relative to a pre-movement baseline, reflecting post-movement cortical synchronization.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  3. Change in Movement-Related Cortical Potential (MRCP) Amplitude

    Amplitude of movement-related cortical potential (MRCP) recorded using scalp electroencephalography during motor execution and motor imagery tasks. MRCP amplitude is measured in microvolts (µV) relative to a pre-movement baseline and reflects cortical activity associated with motor preparation.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  4. Change in Movement-Related Cortical Potential (MRCP) Latency

    Latency of movement-related cortical potentials (MRCPs) recorded using scalp electroencephalography during motor execution and motor imagery tasks. MRCP latency is defined as the time interval in milliseconds (ms) between MRCP onset and movement onset.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  5. Motor Evoked Potential (MEP) Amplitude

    Peak-to-peak amplitude of motor evoked potentials (MEPs) recorded at rest from the target upper limb muscle using surface electromyography following single-pulse transcranial magnetic stimulation of the primary motor cortex. MEP amplitude is measured in millivolts (mV) and reflects corticospinal excitability.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  6. Resting Motor Threshold (RMT)

    Resting motor threshold (RMT) defined as the minimum stimulator intensity required to evoke motor evoked potentials (MEPs) in the target muscle in at least 50% of trials with the muscle at rest. The threshold is expressed as a percentage of maximal stimulator output (% MSO).

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

  7. Change in Weighted Phase Lag Index (wPLI) in the Sensorimotor Network

    Functional connectivity within the sensorimotor network assessed using the weighted phase lag index (wPLI), a phase-based connectivity measure derived from electroencephalography signals during motor execution and motor imagery tasks. wPLI values range from 0 to 1, with higher values indicating stronger phase synchronization between cortical regions.

    Time frame: Baseline and Week 2 (end of intervention, after 10 sessions of iTBS/Sham)

07

Study locations

1 site
  • Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine
    Moscow, Russia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Mar 2027, 10 months later.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 10 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Apr 9, 2026
StartEst.
May 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07520630
Lead sponsor
Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
May 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 9, 2026

Study contacts

Paul D. Egorov
Contact
egorovpd@vk.com
+7-977-878-11-60

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion